AVBPHealthcare · BiotechnologyThe 11 Wall Street analysts covering Arrivent BioPharma, Inc. hold a median 12-month price target of $45 — +54.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Arrivent BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (73): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Revisions (29): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AVBP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +54.4% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $44 → $47 |
| 13 Aug 2026 | BTIG | Reiterates | Buy | $42 |
| 13 Aug 2026 | Citigroup | Maintains | Buy | $43 → $40 |
| 13 Aug 2026 | Guggenheim | Reiterates | Buy | $45 |
| 29 May 2026 | Truist Securities | Maintains | Buy | $43 → $45 |
| 29 May 2026 | Truist Securities | Maintains | Buy | — |
| 13 May 2026 | Citigroup | Maintains | Buy | — |
| 24 Apr 2026 | Citigroup | Maintains | Buy | — |
| 23 Mar 2026 | B. Riley Securities | Maintains | Buy | — |
| 12 Mar 2026 | BTIG | Assumes | Buy | $42 |
| 6 Mar 2026 | Citigroup | Maintains | Buy | — |
| 6 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2026 | Oppenheimer | Reiterates | Outperform | — |
| 23 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 10 Dec 2025 | BTIG | Initiates | Buy | — |
| 25 Nov 2025 | Truist Securities | Initiates | Buy | — |
| 11 Nov 2025 | Citigroup | Maintains | Buy | — |
| 12 Aug 2025 | Citigroup | Maintains | Buy | — |
| 12 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVBP appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 28% of US stocks
Cheaper than 80% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 20% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Arrivent BioPharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ArriVent BioPharma reported its financial results for the second quarter ended June 30, 2026, and highlighted recent company progress.
Why it matters — This quarterly financial update provides AVBP watchers with a snapshot of the company's cash position, spending, and operational milestones for the period.
The 11 Wall Street analysts covering Arrivent BioPharma, Inc. have a median 12-month price target of $45, with estimates ranging from $40 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Arrivent BioPharma, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrivent BioPharma, Inc. 35 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Arrivent BioPharma, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (73 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +54.4% from the last close, and Ticker Nerd's factor model ranks Arrivent BioPharma, Inc. 35 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Arrivent BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $50 over the next 12 months.
Arrivent BioPharma, Inc. returned +46.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Arrivent Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address unmet medical needs in patients with difficult-to-treat diseases, starting with cancers.
The most recent item we track (GlobeNewsWire, 12 Aug 2026): "ArriVent BioPharma Reports Second Quarter 2026 Financial Results". ArriVent BioPharma reported its financial results for the second quarter ended June 30, 2026, and highlighted recent company progress.
Arrivent Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the identification, development, and commercialization of differentiated medicines to address unmet medical needs in patients with difficult-to-treat diseases, starting with cancers. Its lead development candidate, firmonertinib, a tyrosine kinase inhibitor, is being evaluated in multiple clinical trials for various epidermal growth factor receptor mutations in non-small cell lung cancer, including a Phase 3 trial for exon 20 insertion mutations and Phase 1b trials for activating mutations such as P-loop and alpha-c-helix compressing mutations. The company is also advancing ARR-217, an antibody drug conjugate targeting gastrointestinal cancers, and ARR-002 for solid tumors. Arrivent Biopharma Inc. leverages strategic collaborations with partners like Shanghai Allist Pharmaceuticals, Aarvik Therapeutics, Beijing InnoCare Pharma Tech, Jiangsu Alphamab Biopharmaceuticals, and Lepu Biopharma to accelerate global development of innovative oncology therapeutics. Founded in 2021 and headquartered in Newtown Square, Pennsylvania, it operates within the biotechnology sector of pharmaceuticals and biotech, emphasizing novel therapies like next-generation antibody drug conjugates.
CEO Dr. Zhengbin Yao Ph.D. · 77 employees · United States · https://arrivent.com